Relmada Therapeutics Inc. (RLMD) Financial Statements (2024 and earlier)

Company Profile

Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR
CORAL GABLES, FL 33134
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
6/30/2019
6/30/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments96,324148,323211,910117,0919,2172,239
Cash and cash equivalents4,0925,39644,4432,4959,2172,239
Short-term investments92,232142,927167,466114,596  
Receivables  512 7924772
Prepaid expense1,1854,03511,302903521427
Other undisclosed current assets   86   
Total current assets:97,509152,870223,298118,0749,9842,738
Noncurrent Assets
Nontrade receivables    86203273
Property, plant and equipment    1712
Other noncurrent assets433528252525
Total noncurrent assets:433528113235310
TOTAL ASSETS:97,552152,905223,326118,18610,2203,048
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,19512,46915,06112,6032,2421,425
Accounts payable3,5065,26211,1938,346924765
Accrued liabilities8,6897,2073,8684,2571,318659
Debt     364285
Derivative instruments and hedges, liabilities      4,195
Total current liabilities:12,19512,46915,06112,6032,6065,905
Noncurrent Liabilities
Long-term debt and lease obligation      2,656
Long-term debt, excluding current maturities      2,656
Total noncurrent liabilities:      2,656
Total liabilities:12,19512,46915,06112,6032,6068,561
Equity
Equity, attributable to parent85,357140,436208,265105,5837,613(5,513)
Common stock303028163913
Additional paid in capital646,230602,517513,304284,882119,23788,819
Accumulated deficit(560,903)(462,111)(305,067)(179,315)(111,662)(94,344)
Total equity:85,357140,436208,265105,5837,613(5,513)
TOTAL LIABILITIES AND EQUITY:97,552152,905223,326118,18610,2203,048

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
6/30/2019
6/30/2018
Revenues      
Realized investment losses(4,064)(586)(636)(156)  
Cost of revenue
(Cost of Goods and Services Sold)
      (17)
Gross profit:     (17)
Operating expenses(103,702)(161,249)(125,703)(60,839)(12,728)(6,917)
Other undisclosed operating income (loss)4,064586636156 17
Operating loss:(103,702)(161,249)(125,703)(60,839)(12,728)(6,917)
Nonoperating income (expense)4,9114,205(48)1,382(4,590)(2,043)
Investment income, nonoperating      
Interest and debt expense  6,352  (3,774)(6,534)
Loss from continuing operations:(98,792)(150,692)(125,752)(59,456)(21,093)(15,495)
Loss before gain (loss) on sale of properties:(125,752)(59,456)(21,093)(15,495)
Other undisclosed net income     3,774 
Net loss:(98,792)(150,692)(125,752)(59,456)(17,318)(15,495)
Other undisclosed net income (loss) attributable to parent  (6,352)   6,534
Net loss available to common stockholders, diluted:(98,792)(157,044)(125,752)(59,456)(17,318)(8,961)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
6/30/2019
6/30/2018
Net loss:(98,792)(150,692)(125,752)(59,456)(17,318)(15,495)
Comprehensive loss, net of tax, attributable to parent:(98,792)(150,692)(125,752)(59,456)(17,318)(15,495)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: